Athersys, Inc. Pitch Deck (2018): 32-Slide Breakdown

The Athersys (ATHX) investor deck from August 2018 serves as a technical validation tool for a publicly traded biotechnology company. Rather than focusing on early-stage problem/solution narratives, the deck leans heavily into clinical trial results, regulatory designations, and manufacturing moats. With MultiStem as the lead candidate, the company showcases a broad pipeline spanning neurological, cardiovascular, and inflammatory diseases. Key data points include a 23.8% delta in 'excellent outcomes' for stroke patients treated within 36 hours (Slide 17) and a clear transition from 2D cell cu…

Key takeaways

• The company maintains a diverse pipeline with lead programs in Phase 3 for Ischemic Stroke (Slide 2).
• Athersys emphasizes manufacturing as a competitive advantage, transitioning from 2D culture to commercial-scale 3D bioreactors (Slide 9).
• MultiStem's mechanism of action involves modulating the immune response from the spleen to prevent brain tissue loss (Slide 13).
• Clinical data from the Masters-1 trial shows a p < 0.01 significance for early treatment (<36 hours) in stroke patients at one year (Slide 17).
• Biomarker data confirms MultiStem's impact on key inflammatory cytokines like IL-1β (p=0.01) and TNFα (p=0.03) (Slide 21).
• The platform extends beyond stroke to include Acute Respiratory Distress Syndrome (ARDS) and HSC Transplant/GvHD (Slide 2).
• Preclinical data demonstrates reduced inflammation in human lungs with ischemic reperfusion injury (Slide 30).
• The deck highlights regulatory tailwinds including RMAT designation from the FDA and Priority Review from PMDA in Japan (Slide 2).

Frequently asked questions

What is the primary therapeutic candidate discussed in the deck?

The primary candidate is MultiStem, a regenerative medicine product. The deck focuses on its application for Ischemic Stroke, where it is in Phase 3 trials (TREASURE and MASTERS-2), as well as its potential in treating ARDS and other inflammatory conditions.

How does Athersys address the challenge of cell therapy manufacturing?

Slide 9 identifies 'Highly Scalable' manufacturing as a key competitive advantage. It illustrates a progression from traditional 2D culture to 3D bioreactors, and finally to large-scale commercial bioreactors, which is a common bottleneck in the cell therapy industry.

What were the specific clinical outcomes for the stroke trials?

According to Slide 17, patients receiving early MultiStem treatment (<36 hours) showed a 29.6% 'Excellent Outcome' rate at Day 365 compared to 5.8% for the placebo group. This resulted in a 23.8% delta with a statistically significant p-value of <0.01.

What regulatory advantages does Athersys claim?

Slide 2 lists several high-value designations: Fast Track and RMAT (Regenerative Medicine Advanced Therapy) from the FDA, Priority Review from the PMDA in Japan, and Orphan Drug designation from both the FDA and EMA for specific programs.

What is the biological mechanism behind MultiStem?

Slide 13 explains that MultiStem works by downregulating neuroinflammation and upregulating repair. Specifically, it targets the hyperinflammatory response emanating from the spleen following a stroke, which otherwise leads to scarring and tissue loss in the brain.

Athersys, Inc. pitch deck: the facts

Company

Athersys, Inc.

Year

2018

Stage

Public (NASDAQ: ATHX)

Slides

32

Sector

Biotechnology / Regenerative Medicine

Deck type

Investor Overview

Outcome

Active at time of deck (later filed for Chapter 11 in 2024)

Headquarters

Cleveland, Ohio, USA

Athersys, Inc. pitch deck PDF

The full Athersys, Inc. deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the Athersys, Inc. pitch deck was used for

This deck is an October 2018 investor overview presentation for Athersys, Inc., a NASDAQ‑listed cell therapy company (ticker ATHX) focused on its MultiStem platform for critical care and regenerative medicine indications, notably ischemic stroke and ARDS. The company was already public and used the deck to brief investors on its pipeline, late‑stage clinical programs (including the MASTERS‑2 Phase 3 trial and Healios' TREASURE registrational trial), and financial position rather than to market a single private funding round. Around this period Athersys’ primary external capital inflows linked to MultiStem were an equity investment and license expansion payments from Healios K.K. and ongoing access to public capital markets, not a discrete venture round. The deck therefore functions as a public company clinical and corporate update meant to support investor confidence and trading liquidity, and potentially future shelf or follow‑on offerings, rather than a classic startup fundraising pitch.

Business model: Athersys, Inc. is a clinical-stage biotechnology company developing **MultiStem**, an allogeneic cell therapy platform for critical care and regenerative medicine indications including ischemic stroke and acute respiratory distress syndrome (ARDS). Its business model centers on advancing proprietary cell therapy candidates through clinical development and monetizing them via licensing and collabor

Year

2018

Lead investor

Healios K.K.

Investors

Healios K.K. (equity investor and strategic licensee).

Headquarters

Athersys, Inc. is headquartered in Cleveland, Ohio, United States.

Industry

Biotechnology / Regenerative Medicine / Cell Therapy.

Round: Public company strategic financing and license expansion linked to the MultiStem platform and critical care indications, rather than a traditional private venture round.

Raised: Healios made an approximately **$21.1 million** equity investment in Athersys in March 2018 at **$1.76 per share**, and funded a **$20 million** license fee as part of the June 2018 collaboration expansion, supplemented by additional committed payments over time (up to $25 million) and potential milestones and royalties if the collaboration is fully expanded.

Use of funds as presented: The equity investment and license fees from Healios were tied to expanding MultiStem development and commercialization in ischemic stroke, ARDS, trauma, and organ‑bud related indications in Japan and potentially China, providing capital to support Athersys’s clinical programs (including MASTERS‑2 and TREASURE) and broader platform development.

What happened after the Athersys, Inc. deck

The 2018 investor deck captured Athersys at a pivotal moment: initiating the MASTERS‑2 Phase 3 ischemic stroke trial, expanding the Healios collaboration through equity and licensing transactions, and reporting strong cash and contract revenue figures. Subsequently, Athersys has continued to develop MultiStem in stroke and ARDS, publishing exploratory ARDS data and revisiting the design and poweri

• By Q3 2018, Athersys had launched and begun enrollment in the MASTERS‑2 pivotal Phase 3 clinical trial of MultiStem cell
• Healios K.K. was conducting the TREASURE registrational trial in Japan for ischemic stroke using MultiStem, with priorit
• In March 2018, Healios made a $21.1 million equity investment in Athersys at $1.76 per share and deposited $10 million i
• In June 2018, the Healios partnership was expanded to include additional licensed indications such as ARDS and organ‑bud
• In January 2019, Athersys announced summary results from an exploratory Phase 1/2 ARDS study (MUST‑ARDS), reporting favo
• In October 2023, an independent data safety monitoring board concluded that the current 300‑patient sample size in the o

What the Athersys, Inc. deck got right

• Clear positioning as a critical care cell therapy leader. The deck clearly positions Athersys as an established leader in cell therapy and regenerative medicine, listing multiple clinical programs and emphasizing critical care indications where unmet need and potential impact are high, which helps frame a compelling strategic focus.
• Strong regulatory validation for lead stroke program. The ischemic stroke program is backed by multiple regulatory designations—Fast Track and RMAT from FDA, a Special Protocol Assessment, priority review from PMDA for TREASURE, and positive scientific advice from EMA—providing strong external validation and perceived de‑risking that the deck highlights.
• High‑quality strategic partnership and capital from Healios. The collaboration with Healios K.K., including the TREASURE registrational trial in Japan, substantial equity investment, and expanded licenses for ARDS and organ‑bud applications, demonstrates meaningful strategic alignment and non‑dilutive funding that the deck leverages as a major credibility point.
• Compelling product and platform characteristics for MultiStem. The MultiStem product profile slide emphasizes off‑the‑shelf administration, long storage life (>7 years stability data), high production yield (millions of doses per donor), and multiple routes of delivery, which together communicate a robust and scalable therapeutic platform, not just a single asset.
• Broad, staged pipeline providing long‑term optionality. The pipeline slide demonstrates breadth across neurological, cardiovascular, inflammatory/immune, and orthopedic indications with clearly marked clinical stages (preclinical through Phase 3), giving investors a sense of long‑term optionality beyond the lead programs.
• Visible cash balance and growing collaboration revenue. The deck reports a solid financial position with $53.4 million in cash as of Q2 2018 and highlights increased contract revenue from the Healios collaboration, which supports the narrative that Athersys is adequately capitalized to pursue its near‑term development plans.

What could have been stronger

• Limited visibility on cash runway and financing strategy. Although the deck mentions $53.4 million in cash as of Q2 2018 and a "solid financial position", it does not tie this explicitly to a detailed cash runway analysis, burn rate, or financing plan for completing costly Phase 3 trials, which may leave investors uncertain about how long existing capital will last and what follow‑on financings might be required.
• Broad pipeline with unclear prioritization beyond lead indications. The pipeline slide lists numerous indications (neurological, cardiovascular, inflammatory/immune, orthopedic) with varying stages, but the deck—as summarized—emphasizes ischemic stroke and ARDS without clearly prioritizing or rationalizing resources across secondary programs, which could raise questions about focus and portfolio discipline.
• High‑level clinical claims without detailed quantitative data in the visible slides. The deck refers to "compelling clinical data" and multiple regulatory designations (Fast Track, RMAT, SPA, priority review) but, in the extracted text, does not provide granular efficacy statistics, effect sizes, or comparative benchmarks versus standard of care, limiting investors’ ability to independently assess the strength of the data.
• Manufacturing scalability described qualitatively rather than quantitatively. The company positions MultiStem as off‑the‑shelf, long‑term stable and high‑yield, but provides limited numerical manufacturing metrics (e.g., cost of goods per dose, capacity, failure rates) in the text available, which may make it difficult for investors to evaluate scalability and commercial viability despite the qualitative emphasis on manufacturing.

How an investor would read this deck

What draws attention

• Regulatory de‑risking of the lead ischemic stroke program via Fast Track, RMAT designation, and Special Protocol Assessment (SPA), plus positive scientific advice from EMA, which together suggest a well‑validated development path.
• The strategic collaboration with Healios K.K., including the TREASURE registrational trial, equity investment, and license expansion for ARDS and organ‑bud related indications, as a key external validation and non‑dilutive funding source.
• The off‑the‑shelf nature of MultiStem, long storage life (>7 years stability data), and high production yield enabling millions of doses from each donor bank, which underpin the commercial scalability story for an allogeneic cell therapy.
• The solid cash position reported ($53.4 million as of Q2 2018) and increased contract revenue from Healios, which support ongoing Phase 3 development while highlighting reliance on partnerships and capital markets.

Risks that stand out

• Clinical risk that MultiStem may not achieve its primary endpoints in pivotal trials despite early‑stage and exploratory data characterized as compelling in 2018; this was later underscored by a 2023 interim analysis indicating that a 300‑patient sample size was insufficiently powered for the primar
• Regulatory and development risk tied to complex trial designs and reliance on special designations (SPA, RMAT, Fast Track, priority review); changes in regulatory expectations or trial outcomes could delay approval or require redesign.
• Financing risk for a clinical‑stage company running expensive global Phase 3 trials, dependent on public markets and partner funding; adverse data or market conditions could constrain access to capital despite prior cash balances and collaborations.
• Execution risk around manufacturing scale‑up and commercialization of an allogeneic cell therapy, where long‑term stability and high yields must be matched with regulatory‑grade CMC systems and competitive cost structures.
• Partner concentration risk related to Healios K.K. carrying important rights and responsibilities in key territories; changes in the partner’s strategy, performance, or financial health could materially affect Athersys’s path to market.

Questions this deck invites

• What is the detailed clinical performance of MultiStem in ischemic stroke (e.g., mRS shift outcomes, functional recovery rates, safety) in Phase 2 and early Phase 3, and how do these compare to standard of care therapies?
• What is the projected cash runway based on 2018 burn rates, and what specific financing plans (public offerings, additional partnerships, non‑dilutive grants) are in place to fund completion of MASTERS‑2 and other key trials?
• How robust and scalable is Athersys’s manufacturing process for MultiStem in terms of cost of goods, batch consistency, capacity, and regulatory compliance, given the claim of millions of doses per donor and >7‑year stability?
• What specific commercial rights and economic terms (milestones, royalties, territory splits) apply across the Healios collaboration and any other licensing agreements, and how do these shape Athersys’s long‑term revenue potential?
• How have subsequent clinical developments (e.g., the interim analysis of MASTERS‑2 in 2023) affected the risk‑reward profile for investors who relied on the 2018 deck’s characterization of the ischemic stroke program?

What founders can take from the Athersys, Inc. deck

• A public‑company deck that clearly emphasizes regulatory designations (SPA, RMAT, Fast Track, priority review, EMA scientific advice) can materially strengthen the perceived de‑risking of a lead program, especially in complex indications like ischemic stroke.
• Showcasing a strategic collaboration (Healios’ TREASURE trial, equity investment, and license expansion) with specific financial and territorial terms demonstrates external validation and diversified funding beyond traditional equity, which can be persuasive in capital‑intensive cell therapy develop
• Positioning a platform therapy such as MultiStem around concrete operational attributes—off‑the‑shelf use, long stability, high production yield, multiple administration routes—helps investors connect the scientific story to commercial scalability.
• Including a broad pipeline overview spanning neurological, cardiovascular, inflammatory/immune, and orthopedic indications signals long‑term upside, but it also highlights the importance of clarifying prioritization and resource allocation to avoid perceptions of over‑extension.
• Reporting specific cash figures (e.g., $53.4 million as of Q2 2018) and collaboration‑derived revenues (from Healios) provides reassurance on funding capacity, though sophisticated investors will still expect explicit runway and financing plans.
• Subsequent clinical events (such as the 2023 interim analysis of MASTERS‑2 showing insufficient power at the planned sample size) illustrate why investors must treat optimistic late‑stage narratives in decks as snapshots in time and continuously update their risk assessments as new data emerge.

Athersys, Inc. pitch deck: common questions

What does Athersys, Inc. do?

Athersys, Inc. is a clinical-stage biotechnology company developing **MultiStem**, an off‑the‑shelf allogeneic cell therapy based on its proprietary MAPC (multipotent adult progenitor cell) technology, targeting critical care indications such as ischemic stroke and ARDS as well as other regenerative medicine applications.

What is Athersys’s lead program and clinical focus in this deck?

In the 2018 investor materials, Athersys highlights ischemic stroke (MASTERS‑2 Phase 3) and ARDS (MUST‑ARDS exploratory study and Healios’ rights in Japan) as lead indications, with additional programs in neurological, cardiovascular, inflammatory/immune, and orthopedic areas shown on its regenerative medicine pipeline slide.

What stage was Athersys at when this 2018 deck was presented?

The deck describes Athersys as a NASDAQ‑listed company under the symbol **ATHX**, emphasizing its status as an established leader in cell therapy and regenerative medicine with multiple clinical programs and a solid financial position (cash of $53.4 million as of Q2 2018).

Who is Athersys’s main strategic partner mentioned in the deck and what is the collaboration?

Athersys’ key partner in this deck is **Healios K.K.**, a regenerative medicine company in Japan that is conducting the TREASURE registrational trial in ischemic stroke and has expanded its license to include ARDS and organ‑bud related applications, supported by a $21.1 million equity investment and a $20 million license fee.

What is MultiStem and how does the deck position this therapy?

The deck describes MultiStem as an off‑the‑shelf cell therapy derived from proprietary MAPC technology, administered systemically or locally without tissue matching or immune suppression, with long storage life (over seven years of stability data) and high production yield enabling millions of doses from each donor bank.

Sources

Funding and outcome facts on this page were researched on 2026-08-21 from the pages below.

• Athersys and Healios Announce Binding Letter of Intent to Expand...
• Investors - Events - Athersys, Inc.
• Athersys Announces Enrollment of First Patient in Masters-2 Phase 3 Study of Multistem® Treatment for Ischemic Stroke
• Developing New Therapies for Critical Care and
• Athersys Reports First Quarter 2018 Results - Athersys, Inc.
• Athersys Announces Financial Results for Fourth Quarter and Full Year 2018
• [PDF] Athersys, Inc. Overview
• ATHERSYS, INC / NEW (Form: 10-K, Received: 03/15/2019 06:13:29)

Athersys, Inc. pitch deck slides

What each slide of the Athersys, Inc. pitch deck says

Slide 1

Athersys | Company Overview NASDAQ: ATHX www.Athersys.com August, 2018

Slide 2

Forward Looking Statements This presentation has been prepared by us solely for information purposes. This presentation includes, and our responses to various questions may include, "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the "safe harbor" created by those sections. These forward-looking statements relate to, among other things, the expected timetable for development of our product candidates, our growth strategy and our future financial performance, including our operations, economic performanc…

Slide 3

A Company Snap Shot (NASDAQ: ATHX) " Established leader in the development of innovative cell therapy and regenerative medicines Multiple clinical programs — emphasis on Critical Care indications Lead Program Focused on Ischemic Stroke with compelling clinical data & multiple significant regulatory designations Partnered with Healios KK — leading regenerative medicine company in Japan (conducting TREASURE registrational trial) MultiStem Phase 3 Study for Ischemic Stroke enrolling (with Fast Track and RMAT designation) and being conducted under Special Protocol Assessment (SPA) obtained from FDA Robust Clinical & Preclinical Pipeline Solid Financial Position ( $53.4 million as of Q2, 2018)

Slide 4

A Our Focus: Development of best in class regenerative medicine therapies for areas of substantial unmet medical need Neurological, Cardiovascular, Inflammatory & Immune and Other Indications with an Emphasis in the Critical Care Segment Q-

Slide 5

ATHX Regenerative Medicine Pipeline Neurological Ischemic Stroke* Traumatic Brain Injury Multiple Sclerosis Spinal Cord Injury Cardiovascular Acute Myocardial Infarction PVD/PAD/CLI Congestive Heart Failure Inflammatory & Immune HSC Transplant / GYHD** Acute Respiratory Distress Syndrome Solid Organ Transplant Support Orthopedic Bone Allograft (map3®technology)*** Precinical IND/CTA Phasel Phase2 Phose3 NDA/BLA Commercol TREASURE (Healios) - enrollment ongoing Priority review designation from PMDA TERS-2 (Athersys) - enrollment ongoing SPA, Fast Track and RMAT Designation from FDA & Positive Scientific Advice from EMA Ability to move directly to Phase 2 POC ————— enrollmefikongoing } Abilit…

Slide 6

Experienced Executive Leadership Ras — | ——— ee ure ALLIANCE. Stanford Gil Van Bokkelen, PhD Chairman & CEO Cr ‘REGENERATIVE MEDICINE McKinsey&Company WER & William BJ Lehmann President & COO @ Stanifoed John Harrington, PhD CSO Exec. VP, Board member AAIVIGEN Or Scripps @) Stanford Senior VP Global Regulatory EVMS oS MERCK Manal Morsy, MD, PhD < Affairs Gohmsenfohmon ®ic Laura Campbell Senior VP Finance EY 6

Slide 7

A proqetfetie MULTISTEM CELL THERAPY Athersys inec ¢ Based on Proprietary Promotes Healing and Given Systemically or Long Storage Life and MAPC Technology Tissue Repair Locally High Production Yield Off the shelf administration Works through multiple IV, catheter, injection, > 7 years of stability data, with no tissue matching or mechanisms of action matrix/implant and yield of millions of doses immune suppression required from each donor bank

Slide text above is read directly from the Athersys, Inc. deck PDF embedded on this page.

Related fundraising guides (24)

• Checkstep Pitch Deck Teardown: A 7-Slide Product Showcase for AI Content Moderation
• BetterManager Pitch Deck Teardown: A $16M Series A Built on Traction and Google Pedigree
• Amogy Pitch Deck Teardown: Solving the Energy Density Gap for Heavy-Duty Mobility
• Hedra Pitch Deck Teardown: A $32M Series A Built on Capital-Efficient AI Research
• Odeko Pitch Deck Teardown: A Masterclass in Obfuscating Real Traction Numbers
• Innovafeed Pitch Deck Teardown: A $250M Masterclass in Industrial Scale and Strategic Partnerships
• Heura Pitch Deck Teardown: Dominating the Mediterranean Plant-Based Market
• Fintor Pitch Deck Teardown: A $6.2M Seed Round Built on Fractional Real Estate Liquidity
• EcoLocked Pitch Deck Teardown: Decarbonizing Construction via Biochar Admixes
• Clutch Wallet Pitch Deck Teardown: A $800k Pre-Seed Bet on Web3 Inclusivity
• Bramble Energy Pitch Deck Teardown: Leveraging PCB Supply Chains for Hydrogen Fuel Cells
• Arist Pitch Deck Teardown: The $12M Series A Memo Strategy for Micro-Learning
• Aceiss Pitch Deck Teardown: A Masterclass in Team Credibility and Problem Framing
• Thematic Pitch Deck Teardown: Leveraging Creator Networks for Scalable Music Promotion
• Layla Pitch Deck Teardown: A $3M Seed Round Built on AI-Powered Travel Discovery
• Hint Health Pitch Deck Teardown: Scaling Direct Primary Care Infrastructure
• Goldcast Pitch Deck Teardown: Turning Virtual Events Into A High-Velocity B2B Revenue Engine
• Eliyan Pitch Deck Teardown: Solving the Chiplet Interconnect Bottleneck for AI
• Code First Girls Pitch Deck Teardown: A Masterclass in B2B Social Impact Scaling
• Buynomics Pitch Deck Teardown: A Data-Driven Case for Behavioral Pricing Intelligence
• Assembly Pitch Deck Teardown: A Product-First Series A Narrative Focused on Retention
• AgBiome Pitch Deck Teardown: A $116M Series D Masterclass in Platform Validation
• Moonlight Pitch Deck Teardown: A Community-First Approach to Remote Engineering
• Viso Pitch Deck Teardown: A 42-Slide Masterclass in Computer Vision Infrastructure

Decks from the same year (1)

• 2018 pitch deck examples

Decks from the same region (1)

• US pitch deck examples

Browse companies alphabetically (1)

• Pitch decks from companies starting with A

More pitch deck teardowns (16)

• AstroPrint Pitch Deck Breakdown: A Visual-First Approach to 3D Printing Complexity
• Astrum Investment Management Pitch Deck Teardown: A Specialized Sale-Leaseback Strategy
• ATEC Pitch Deck Breakdown: A $6.5M Carbon Story With No Carbon Price
• Atento Pitch Deck Teardown: Transitioning from a Cost Center to a LatAm CRM Leader
• Atexto Pitch Deck Breakdown: Efficiency and Unit Economics in the AI Training Data Market
• Athennian Pitch Deck Breakdown: A Masterclass in Competitive Displacement and Market Timing
• Athina Pitch Deck Teardown: A Pre-Soylent Look at the 'Netflix for Books' Model
• At Home Nursing Services Pitch Deck Teardown: A Healthcare M&A Rollup Strategy
• ATLAS Pitch Deck Teardown: A Broad Vision for a Crypto-Social 'Super-App'
• AtoB Pitch Deck Breakdown: A Masterclass in Vertical Fintech and Market Expansion
• Atom Limbs Pitch Deck Breakdown: Disrupting Prosthetics with a Hardware-as-a-Service Model
• Atomwise Pitch Deck Breakdown: Building a $5.5B Ecosystem for AI-Driven Medicine
• Atropos Health Pitch Deck Teardown: A Masterclass in Academic Credibility for Clinical AI
• AT&T × Time Warner Pitch Deck Breakdown: A $106B Vertical Integration Thesis
• Auctio Pitch Deck Breakdown: A Minimalist Approach to B2B Referral Management
• Audience Town Pitch Deck Breakdown: A Vertical AdTech Play for the $1T Real Estate Market

Recently published pitch deck teardowns (12)

• Little Journey Pitch Deck Teardown: Quantifying the Financial Cost of Pediatric Patient Anxiety
• LogRock Pitch Deck Teardown: A $3.5M Seed Masterclass in Niche Compliance Automation
• LTV.ai Pitch Deck Teardown: A $5.2M Series A Case Study in AI-Native Marketing
• Lumiform Pitch Deck Teardown: A Product-First Masterclass in Workflow Automation
• Lunio Pitch Deck Teardown: A $15M Series A Masterclass in Cybersecurity Pedigree
• LucidLink Pitch Deck Teardown: Solving the Latency Gap in Remote Creative Collaboration
• Meliora Therapeutics Pitch Deck Teardown: A $11M Seed Case for AI-Driven Oncology Efficiency
• Micro Pitch Deck Teardown: A Developer-Centric Play for Unified Cloud APIs
• Miren Pitch Deck Teardown: A $10,000 Pre-Seed Case Study in Mission-Driven Fintech
• Misha's Kind Foods Pitch Deck Teardown: A Case Study in CPG Traction and Clean Label Branding
• Moleaer Pitch Deck Teardown: A Case Study in Industrial Hard-Tech Proof Points
• Moonlight Pitch Deck Teardown: A Community-First Approach to Remote Engineering

Fundraising library · Pitch deck examples · Investor directory · Founder database